{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:34:36Z","timestamp":1784396076896,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-023"],"award-info":[{"award-number":["CIRP-SYSUCC-023"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115437","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:54:32Z","timestamp":1745582072000},"page":"115437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)\uff1a A phase III crossover trial"],"prefix":"10.1016","volume":"222","author":[{"given":"Lulu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2025.115437_bib1","first-page":"204","article-title":"Testicular cancer: new developments, molecular pathology, and current research keynote","volume":"44","author":"Lopez-Beltran","year":"2023","journal-title":"Pathol (Heidelb, Ger)"},{"issue":"3","key":"10.1016\/j.ejca.2025.115437_bib2","first-page":"580","article-title":"Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors","volume":"2","author":"Singh","year":"2019","journal-title":"Cancer Drug Resist (Alhambra, Calif)"},{"issue":"12","key":"10.1016\/j.ejca.2025.115437_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1634\/theoncologist.2015-0128","article-title":"Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic Chemotherapy-Induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21","volume":"20","author":"Kim","year":"2015","journal-title":"oncologist"},{"issue":"8","key":"10.1016\/j.ejca.2025.115437_bib4","first-page":"2161","article-title":"Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy","volume":"22","author":"Hamada","year":"2014","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115437_bib5","first-page":"2837","article-title":"Phase II study of fosaprepitant\u2009+\u20095HT3 receptor antagonist\u2009+\u2009dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a hoosier cancer research network study","volume":"24","author":"Adra","year":"2016","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2025.115437_bib6","first-page":"1293","article-title":"Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer","volume":"15","author":"Einhorn","year":"2007","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115437_bib7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","article-title":"Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy","volume":"45","author":"Jordan","year":"2009","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"issue":"6","key":"10.1016\/j.ejca.2025.115437_bib8","first-page":"1561","article-title":"Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy","volume":"21","author":"Olver","year":"2013","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115437_bib9","doi-asserted-by":"crossref","unstructured":"Fumimasa Fukuta H.K., Hiroshi Hotta,3 Naoki Itoh, Manabu Okada,Tetsuya Shindo,Yuki Kyoda,6 Kohei Hashimoto, Ko Kobayashi,Toshiaki Tanaka,and Naoya Masumori Antiemetic Efficacy and Safety of Palonosetron on Days 1 and 5 with Aprepitant and Dexamethasone during Bleomycin, Etoposide, andCisplatinChemotherapy in Patients with Germ Cell Tumor: A Prospective Study. European Journal of Cancer Care. 8 July 2024;2024\/8838889.","DOI":"10.1155\/2024\/8838889"},{"issue":"32","key":"10.1016\/j.ejca.2025.115437_bib10","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"Albany","year":"2012","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"9 Pt B","key":"10.1016\/j.ejca.2025.115437_bib11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1464-410X.2009.08864.x","article-title":"Management of good risk germ-cell tumours","volume":"104","author":"Troost","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2025.115437_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/943618","article-title":"Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"BioMed Res Int"},{"issue":"2","key":"10.1016\/j.ejca.2025.115437_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacol: Publ Am Coll Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115437_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(00)00037-6","article-title":"Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium","volume":"390","author":"Bymaster","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"1-2","key":"10.1016\/j.ejca.2025.115437_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejca.2025.115437_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.ejca.2025.115437_bib17","first-page":"6225","article-title":"Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study","volume":"30","author":"Gao","year":"2022","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115437_bib18","first-page":"47","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents","volume":"32","author":"Herrstedt","year":"2023","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115437_bib19","article-title":"Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement","volume":"19","author":"Einhorn","year":"2011","journal-title":"Support Care Cancer: J Multinatl Assoc Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.115437_bib20","first-page":"637","article-title":"Practical management of chemotherapy-induced nausea and vomiting","volume":"19","author":"Wiser","year":"2005","journal-title":"Oncol (Williston Park, NY"},{"issue":"2","key":"10.1016\/j.ejca.2025.115437_bib21","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1188\/18.CJON.E31-E36","article-title":"Cisplatin-Based therapy and CINV: optimal antiemetics during germ cell testicular cancer treatment","volume":"22","author":"Mastrangelo","year":"2018","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ejca.2025.115437_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-010-1519-2","article-title":"Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance p concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients","volume":"68","author":"Takahashi","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115437_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.31557\/APJCP.2021.22.3.871","article-title":"Pharmacokinetics of dexamethasone when administered with fosaprepitant for Chemotherapy-Induced nausea and vomiting and differences in Dose-Dependent antiemetic effects","volume":"22","author":"Shimamoto","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ejca.2025.115437_bib24","doi-asserted-by":"crossref","unstructured":"Zhou H., Zhao Y., Zhang M., et al. Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2024:Jco2401308.","DOI":"10.1200\/JCO-24-01308"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:58Z","timestamp":1762342558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"alternative-id":["S0959804925002187"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115437","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)\uff1a A phase III crossover trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115437"}}